Aman U Buzdar Selected Research

Estrogen Receptors

1/2019	Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction Between SLC38A7 and ALPPL2.
7/2017	SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway.
1/2016	Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426).
5/2013	Using multiple targeted therapies in oncology: considerations for use, and progress to date in breast cancer.
4/2013	TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression.
11/2011	Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.
7/2011	Predictive algorithms for adjuvant therapy: TransATAC.
5/2011	Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy.
3/2011	Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning.
6/2010	Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Aman U Buzdar Research Topics

Disease

146	Breast Neoplasms (Breast Cancer) 01/2022 - 01/2002
56	Neoplasms (Cancer) 01/2022 - 01/2002
18	Pathologic Complete Response 01/2022 - 06/2005
7	Neoplasm Metastasis (Metastasis) 06/2010 - 08/2002
6	Residual Neoplasm 04/2017 - 04/2004
5	Endometrial Neoplasms (Endometrial Cancer) 02/2008 - 12/2002
4	Disease Progression 01/2018 - 05/2004
4	Uterine Hemorrhage (Uterine Bleeding) 02/2008 - 12/2002
3	Lymphatic Metastasis 05/2012 - 03/2006
3	Cardiotoxicity 09/2007 - 11/2002
3	Carcinoma (Carcinomatosis) 02/2006 - 04/2004
2	Triple Negative Breast Neoplasms 01/2022 - 05/2013
2	Exanthema (Rash) 04/2015 - 01/2013
2	Febrile Neutropenia 01/2011 - 02/2010
2	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2011 - 01/2007
2	Cognitive Dysfunction 07/2010 - 08/2004
2	Obesity 09/2008 - 09/2008
2	Lobular Carcinoma 11/2006 - 01/2005
2	Inflammatory Breast Neoplasms 03/2006 - 02/2004
2	Male Breast Neoplasms (Male Breast Cancer) 12/2005 - 06/2002
2	Heart Failure 06/2005 - 11/2002
1	Overweight 01/2016
1	Pain (Aches) 04/2015
1	Digestive System Diseases 01/2013
1	Anemia 07/2011
1	Infections 01/2011
1	Thrombocytopenia (Thrombopenia) 01/2011
1	Myalgia 02/2010
1	Arthralgia (Joint Pain) 09/2008
1	Arthritis (Polyarthritis) 09/2008
1	Osteoporosis 07/2008

Drug/Important Bio-Agent (IBA)

33	Tamoxifen FDA LinkGeneric 05/2013 - 01/2002
31	Estrogen ReceptorsIBA 01/2019 - 01/2002
28	Anastrozole (Arimidex)FDA LinkGeneric 01/2021 - 06/2002
28	Hormones (Hormone)IBA 04/2015 - 10/2002
27	Aromatase InhibitorsIBA 01/2020 - 11/2002
22	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022 - 01/2002
21	Paclitaxel (Taxol)FDA LinkGeneric 12/2013 - 04/2002
20	Fluorouracil (Carac)FDA LinkGeneric 12/2013 - 01/2002
19	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 01/2002
16	Trastuzumab (Herceptin)FDA Link 03/2016 - 06/2005
12	Letrozole (Femara)FDA LinkGeneric 05/2007 - 11/2002
11	Progesterone Receptors (Progesterone Receptor)IBA 05/2013 - 10/2002
11	AnthracyclinesIBA 05/2012 - 05/2002
9	exemestane (Aromasin)FDA Link 01/2020 - 01/2003
8	Estrogens (Estrogen)FDA Link 01/2021 - 12/2002
8	human ERBB2 proteinIBA 04/2017 - 06/2005
7	Epirubicin (Ellence)FDA LinkGeneric 12/2013 - 06/2005
6	Biomarkers (Surrogate Marker)IBA 01/2021 - 02/2008
6	Fulvestrant (Faslodex)FDA Link 01/2020 - 01/2003
5	taxaneIBA 07/2011 - 10/2004
5	Megestrol Acetate (Borea)FDA LinkGeneric 01/2004 - 11/2002
4	ErbB Receptors (EGF Receptor)IBA 04/2015 - 10/2002
4	Taxoids (Taxanes)IBA 12/2009 - 01/2003
3	Aromatase (CYP19)IBA 07/2017 - 12/2002
3	Lapatinib (GW572016)FDA Link 03/2016 - 01/2013
3	Selective Estrogen Receptor Modulators (SERM)IBA 09/2013 - 07/2008
3	Estrogen Receptor AntagonistsIBA 09/2008 - 01/2003
3	Estrogen Receptor Modulators (Antiestrogen)IBA 02/2006 - 01/2003
2	DNA (Deoxyribonucleic Acid)IBA 04/2013 - 03/2011
2	Docetaxel (Taxotere)FDA Link 05/2012 - 03/2012
2	Capecitabine (Xeloda)FDA Link 03/2012 - 03/2008
2	Messenger RNA (mRNA)IBA 11/2011 - 01/2007
2	Proteins (Proteins, Gene)FDA Link 10/2010 - 09/2004
2	Tumor Biomarkers (Tumor Markers)IBA 10/2010 - 01/2008
2	LY 353381 (LY353381)IBA 07/2008 - 11/2007
2	Epothilones (Epothilone)IBA 03/2008 - 12/2007
2	thiamine triphosphorate (TTP)IBA 09/2004 - 05/2004
1	tipifarnib (R115777)IBA 01/2018
1	Gemcitabine FDA Link 01/2018
1	Estrone FDA Link 07/2017
1	Androstenedione (4 Androstene 3,17 dione)IBA 07/2017
1	TOR Serine-Threonine KinasesIBA 05/2013
1	Epidermal Growth Factor (EGF)IBA 05/2013
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 05/2013
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 05/2013
1	Estradiol (Delestrogen)FDA LinkGeneric 04/2013
1	N 30IBA 05/2012
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 05/2012
1	MicroRNAs (MicroRNA)IBA 05/2012
1	Carboplatin (JM8)FDA LinkGeneric 05/2012
1	HematinicsIBA 07/2011
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2011
1	Blood Proteins (Serum Proteins)IBA 10/2010
1	Albumin-Bound Paclitaxel FDA Link 02/2010
1	Growth Factor ReceptorsIBA 09/2008
1	LipidsIBA 07/2008
1	desoxyepothilone B (epothilone D)IBA 03/2008
1	ixabepilone (BMS 247550)FDA Link 03/2008

Therapy/Procedure

56	Therapeutics 01/2019 - 01/2002
52	Drug Therapy (Chemotherapy) 01/2019 - 01/2002
34	Neoadjuvant Therapy 01/2022 - 01/2002
10	Adjuvant Chemotherapy 01/2013 - 01/2002
9	Radiotherapy 01/2007 - 07/2002
8	Mastectomy (Mammectomy) 07/2006 - 01/2002
4	Segmental Mastectomy (Lumpectomy) 03/2011 - 04/2002
2	Aftercare (After-Treatment) 10/2004 - 02/2004
1	Withholding Treatment 07/2010
1	Lymph Node Excision (Lymph Node Dissection) 06/2010
1	Combined Modality Therapy 12/2008